Proximal Ventures raises debut fund to back startups bringing AI to drug development (opens techcrunch.com)
Former SignalFire investor Sahir Raoof's first fund targets AI in pharma.
From Latent Space: Leash Biosciences built a platform to physically measure thousands of proteins against millions of molecules. In this followup to our Leash Bio podcast with cofounder Ian Quigley, he returns to discuss the release of Minos, Leash’s framework of pre-measured experimental worlds that scientific…
Former SignalFire investor Sahir Raoof's first fund targets AI in pharma.
Oura buys Counsel Health for $625M weeks after postponing its own IPO; Oura added Counsel's AI chatbot to its app earlier this year.
We help the labs behind your medicines deliver study results 10x faster.
The Alphabet-owned AI drug discovery company would raise roughly $5B at about a $50B valuation, after a $2.1B round in May.
Opentrons will use the money to scale its lab robotics, software and data infrastructure.